HA
DYN icon

HHLR Advisors’s Dyne Therapeutics DYN Stock Holding History

HHLR Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-478,401
Closed -$5.51M – 63
2023
Q1 		$5.51M Sell
478,401
-461,247
-49% -$5.99M 0.1% 50
2022
Q4 		$10.9M Sell
939,648
-60,352
-6% -$698K 0.23% 37
2022
Q3 		$12.7M Hold
1,000,000
– – 0.33% 33
2022
Q2 		$6.87M Hold
1,000,000
– – 0.15% 40
2022
Q1 		$9.64M Hold
1,000,000
– – 0.2% 35
2021
Q4 		$11.9M Hold
1,000,000
– – 0.18% 45
2021
Q3 		$16.2M Hold
1,000,000
– – 0.21% 49
2021
Q2 		$21M Hold
1,000,000
– – 0.22% 51
2021
Q1 		$15.5M Buy
1,000,000
+400,000
+67% +$7.74M 0.15% 54
2020
Q4 		$12.6M Hold
600,000
– – 0.1% 67
2020
Q3 		$12.1M Buy
+600,000
New +$13.2M 0.09% 59

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HHLR Advisors's DYN Position: Q2 2023 in Review

HHLR Advisors sold out of Dyne Therapeutics (DYN) in Q2 2023, closing a stake of 478,401 shares — an estimated $5.51M sold.

HHLR Advisors first reported a position in DYN in Q3 2020 and held it in 11 quarters. The position peaked at $21M in Q2 2021. 118 funds tracked by Wall St. Rank hold DYN as of Q2 2023.

  • HHLR Advisors reported no remaining Dyne Therapeutics position as of Q2 2023 after selling out during the quarter.
  • HHLR Advisors sold 478,401 Dyne Therapeutics shares in Q2 2023, an estimated $5.51M.
  • HHLR Advisors first reported a position in Dyne Therapeutics in Q3 2020 and held it in 11 quarters.
  • HHLR Advisors's Dyne Therapeutics position peaked at $21M in Q2 2021.
  • 118 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2023.

Based on HHLR Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.